The Medicaid Drug Rebate Program (MDRP) official page explains how federal and state governments work with drug manufacturers to reduce the cost of outpatient prescription medicines for Americans enrolled in Medicaid.
Under this program, drug companies must pay rebates to state Medicaid programs for covered drugs dispensed to Medicaid beneficiaries. These rebates help lower the net cost of drugs and reduce spending for both states and the federal government.
Section 1927 of the Social Security Act authorizes the Medicaid Drug Rebate Program and outlines the program’s legal structure.
What Is the Medicaid Drug Rebate Program
The MDRP is a federal program managed by the Centers for Medicare & Medicaid Services (CMS).
It requires drug manufacturers to sign a National Drug Rebate Agreement (NDRA) with the U.S. Department of Health and Human Services to have their outpatient prescription drugs covered under state Medicaid plans.
States use these rebates to offset prescription drug costs, and manufacturers pay rebates on a quarterly basis.
How Are Rebates Calculated
Rebates under the Medicaid Drug Rebate Program are calculated using formulas defined in law. For most brand‑name drugs, the rebate is the greater of 23.1 percent of the average manufacturer price (AMP) or the difference between the AMP and the best price offered in the U.S. market.
There is also an inflation‑related rebate for price increases that exceed inflation. For most generic drugs, the rebate is a fixed percentage of the AMP.
CMS calculates the Unit Rebate Amount (URA) based on manufacturer pricing data and provides it to the states to use in invoicing manufacturers.
Who Must Report and What Data Is Required
Participating drug manufacturers must report pricing data, including AMP and best price, to CMS within 30 days after the end of each calendar quarter.
States then report how much of each drug they dispensed to Medicaid patients to the manufacturer. The manufacturer uses this utilization data to compute the rebate amount owed.
This reporting process ensures that rebate amounts reflect actual prices and usage.
When Are Rebate Payments Due
Once a state reports utilization information, manufacturers must compute and pay the rebate amount to the state within 30 days of receiving the utilization report.
States and the federal government share the rebate revenue based on each state’s federal medical assistance percentage (FMAP).
Rebates are generally paid each quarter for drugs dispensed during that quarter.
What Are the Rules for NDRA Agreements
A manufacturer must sign an NDRA with CMS before its drugs are eligible for Medicaid coverage. This agreement must include all covered outpatient drugs the manufacturer markets.
The NDRA becomes effective on the first day of the calendar quarter that begins more than 60 days after CMS accepts it.
If a manufacturer does not enter an NDRA, its drugs cannot be covered by Medicaid under rebate terms.
How Are Disputes and Non‑Payment Handled
If a state and a manufacturer disagree on rebate amounts, they must use the program’s official dispute resolution process. Disputes must focus on the unit basis of rebate calculations rather than dollar amounts or percentages.
Non‑payment issues are not treated as formal disputes but must be addressed separately through program operations.
States may use a state hearing option when a dispute cannot be resolved informally.
What Happens if Reporting Is Late or Incorrect
Manufacturers are required to report AMP, best price, and product information in a timely way. Failure to report correctly or on time can result in compliance issues and enforcement actions.
Recent legal coverage highlights risks for manufacturers who misreport pricing or product details under MDRP rules.
Federal enforcement under the False Claims Act can apply when inaccurate rebate reporting leads to incorrect Medicaid payments.
How Inflation Affects Rebate Payments
The rebate formulas include an inflation component that increases the rebate amount when drug price increases exceed the rate of inflation.
This inflation rebate is calculated based on changes in the average manufacturer price compared with a baseline price adjusted for inflation.
It helps discourage rapid price increases and contributes to Medicaid’s ability to pay lower net prices.
Do States Share Rebates With the Federal Government
The revenue from Medicaid drug rebate payments is shared between states and the federal government according to the FMAP.
Rebates provide financial support to states and federal Medicaid funding, helping control overall prescription drug spending.
Some portions of rebate revenue, such as those tied to history‑based statutory changes, may be fully allocated to the federal government under specific rules.
